CClinicalTrials.gg
Sign In
WithdrawnNCT02784691Updated Feb 7, 2024

Efficiency and Usability of the Iontophoretic Patch Feeligreen Diclofenac in Treating Acute Osteoarthritic Knee Pain

An interventional study of Feeligreen patch in Osteoarthritis, sponsored by Centre Hospitalier Universitaire de Nice. Withdrawn at 1 site in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Because of logistical problems
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate the antalgic efficacity of Feeligreen® patch on osteoarthritic knee pain acute. This patch work by diffusion controlled by iontophoresis allowing an improvement of transdermal diffusion of active (Diclofenac).

02

Conditions studied

  • Osteoarthritis

Browse trials for

03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

Browse Osteoarthritis studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with age above 70 years,
  • Having a knee Arthritis (unilateral or bilateral) for at least 6 months,
  • Pain intensity ≥ 40 mm on a visual analog scale (VAS)
  • Lack of analgesic treatment or analgesic,

Exclusion criteria

Exclusion Criteria:

  • Cognitive disorders : moderate to severe stage or not allowing an understanding of the VAS (as determined by the clinician)
  • A history of chronic inflammatory rheumatic disease,
  • Diagnosis of osteoarthritis of secondary origin,
  • Non-steroidal anti-inflammatory medication within 7 days prior to inclusion,
  • Diagnosis of severe hepatic and renal insufficiency, gastrointestinal bleeding, severe heart failure,
  • Allergy to diclofenac or similar activity substances such as other NSAIDs, aspirin, excipients,
  • Damaged skin
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Patients

    Device: Feeligreen patch

Interventions

  • DeviceFeeligreen patch
06

What researchers measure

Primary outcomes

  1. Intensity reduction of pain

    Measured by Visual Analog Scale

    Time frame: 2 days

07

Study locations

1 site
  • CHU de Nice
    Nice, 06000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02784691
Lead sponsor
Centre Hospitalier Universitaire de Nice
Responsible party
Sponsor
First posted
May 27, 2016
Start date
Oct 2016
Primary completion
Jul 2017 (estimated)
Completion
Jul 2017 (estimated)
Last update
Feb 7, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Osteoarthritis→

Other studies from this sponsor

Centre Hospitalier Universitaire de Nice

Start the discussion